Beginning on day three after tumor inoculation, gels containing 0.2 mg of aPD1 and 0.2 mg of ADA (aPD1/ADA gel) were injected subcutaneously around the tumor inoculation site for three doses, with each given 3 days apart (Figure 1). Here, ADA is linked to neoplasm.